ADIPOQ and type 2 diabetes mellitus: Another 12-week phase 2 study with the administration of Pegbelfermin in patients with obesity and T2DM demonstrated a remarkable increase in HDL and adiponectin levels but no statistically significant decrease in weight, fasting insulin and HbA1C levels were observed (103, 109).